CD44+/CD24-/low在乳腺癌中表达及其临床意义

目的 观察乳腺癌中CD44+/CD24-/low的表达与临床病理特征的关系及其对预后的影响.方法 应用双染免疫组织化学检测144例乳腺癌与30例乳腺良性肿瘤或正常乳腺组织中CD44+/CD24-/low的表达,收集并分析患者的临床病理和随访资料.结果 CD44+/CD24-/low在乳腺良性肿瘤或正常乳腺中表达率为0%～8%,乳腺癌中表达率为0%～75%.67例(46.5%)乳腺癌患者CD44+/CD24-/low表型的细胞>10%,余77例(53.5%)≤10%.CD44+/CD24-/low的表达高低在淋巴结转移(P<0.01)、病理分期(P<0.01)、HER-2表达(P<0.01)以及复发(P<0.01)上差异有统计学意义.CD44+/CD24-/low高表达的肿瘤复发时主要表现为远处转移,尤其是骨转移.CD44+/CD24-/low高表达和低表达的5年无病生存率为65%和82%(P<0.01),5年总生存率为68%和86%(P<0.05),差异有统计学意义.结论 CD44+/CD24-/low的表达可能与乳腺癌的转移有关,有可能作为评估乳腺癌患者预后的参考指标.

The clinical significance of CD44+/CD24-/low in breast cancer

Objective To detect the expression of CD44+/CD24-/low in breast cancer cells, and investigate its relation with clinicopathologic features and prognosis. Methods Double-staining immuno-histochemistry was used to detect the expression of CD44+/CD24-/low on paraffin-embedded tissues of 144 patients and 30 normal or benign breast tissues. Moreover, the clinicopathologic features of patients with breast cancer and follow-up data were analyzed. Results The expression rate of CD44+/CD24-/low ranged from 0% to 8% in normal or benign breast tissues,and from 0% to 75% in breast cancer tissues,respec-tively. The prevalence of CD44+/CD24-/low cells in 67 tumors was > 10%, and ≤10% in the remaining 77 tumors. The expression levels of CD44+/CD24-/low were significantly related with lymph node metasta-sis (P<0.01), pathological stage (P<0.01), HER-2 expression (P<0.01) and recurrence (P< 0.01). Recurrences of tumors with high percentages of CD44+/CD24-/low cells were mainly distant, par-ticularly osseous metastasis. The 5-year disease-free survival rate in high and low expression of CD44+/CD24-/low was 65% and 82% respectively (P<0.01), and 5-year overall survival rats was 68% and 86% respectively (P<0.05). Conclusion The expression of CD44+/CD24-/low was possibly associated with breast cancer metastasis and survival, and can be used a reference indicator to evehate the prognosis of the patients with breast cancer.